Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 7/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.49 |
| ▸ | SMYD3 | Q9H7B4 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5946344 | 1.00 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL5946342 | 1.00 | PARP1 (0.57) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL7000081 | 0.86 | PARP1 (0.55) | PARP1PDE3BPDE3ASMYD3MAOB | |
| SCHEMBL6991828 | 0.83 | PARP1 (0.49) | PARP1PDE3BPDE3ASMYD3USP2 | |
| SCHEMBL7981172 | 0.81 | PARP1 (0.35) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL4970388 | 0.81 | BRD4 (0.44) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL10130302 | 0.79 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL5670717 | 0.79 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL10130365 | 0.79 | PARP1 (0.62) | PARP1PDE3BPDE3ASMYD3BRD4 | |
| SCHEMBL496236 | 0.78 | PARP1 (0.60) | PARP1PDE3BPDE3ASMYD3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-6191127-B1 | ANTIINFLAMMATORY AGENTS, AUTOIMMUNE DISEASES, CARDIOVASCULAR DISORDERS, NERVOUS SYSTEM DISORDERS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065217-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | MRGPRX2, MRGPRX1, MRGPRX4 | PARP1 4425/4885PDE3B 1112/4885PDE3A 824/4885 |
| US-20110251177-A1 | 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES | TYMP, DPYD, TYMS | PARP1 207/4885PDE3B 533/4885PDE3A 557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.